Get Premium to unlock powerful stock data
NAS:MRSN (USA)  
Mersana Therapeutics Inc logo

Mersana Therapeutics Inc

$ 4.88 +0.25 (+5.4%) 10:08 PM EST
P/E:
At Loss
P/B:
2.92
Market Cap:
$ 473.32M
Enterprise V:
$ 256.69M
Volume:
955.74K
Avg Vol (2M):
1.41M
Also Trade In:
Volume:
955.74K
Market Cap $:
473.32M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.41M
Enterprise Value $:
256.69M
PB Ratio:
2.92
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Mersana Therapeutics Inc
NAICS : 325412 SIC : 2834
840 Memorial Drive, Cambridge, MA, USA, 02139
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Name Current Vs Industry Vs History
Cash-To-Debt 6.11
Equity-to-Asset 0.54
Debt-to-Equity 0.27
Debt-to-EBITDA -0.21
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.85
Distress
Grey
Safe
Beneish M-Score -2.56
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 71.71
9-Day RSI 69.55
14-Day RSI 66.56
6-1 Month Momentum % -48.87
12-1 Month Momentum % -74.81

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.28
Quick Ratio 4.28
Cash Ratio 4.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -46.9

Financials (Next Earnings Date:2022-08-05 Est.)

MRSN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:MRSN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2.069
EPS (TTM) ($) -2.49
Beta 2.27
Volatility % 70
14-Day RSI 66.56
14-Day ATR ($) 0.335342
20-Day SMA ($) 4.0045
12-1 Month Momentum % -74.81
52-Week Range ($) 2.68 - 14.8
Shares Outstanding (Mil) 96.99

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Mersana Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More